Top

Published in:

Open Access 01-06-2018 | Review

A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?

Authors: Yishay Szekely, Yaron Arbel

Published in: Cardiology and Therapy | Issue 1/2018

Abstract

Cardiovascular diseases are the leading cause of death worldwide. Research in the last two decades has emphasized the inflammatory process as a key component in the pathogenesis of many of them. The Interleukin-1 family is a pivotal element of inflammation and has been well studied as a therapeutic target in various inflammatory states. Recent trials have explored the effect of Interleukin-1 blockade in cardiovascular diseases and initial evidence of the relevance of such treatment in this field of medicine accumulate. This review will describe the role of Interleukin-1 in heart diseases and the potential therapeutic effect of its blockade in such diseases.

Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720–32. https://doi.org/10.1182/blood-2010-07-273417.CrossRefPubMedPubMedCentral

Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358(20):2148–59. https://doi.org/10.1056/NEJMra0800239.CrossRefPubMed

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. https://doi.org/10.1056/NEJMra043430.CrossRefPubMed

Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol. 2016;91:114–22. https://doi.org/10.1016/j.yjmcc.2015.12.024.CrossRefPubMed

Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart Br Card Soc. 2015;101(14):1159–68. https://doi.org/10.1136/heartjnl-2014-306362.CrossRef

Elamm C, Fairweather D, Cooper LT. Pathogenesis and diagnosis of myocarditis. Heart Br Card Soc. 2012;98(11):835–40. https://doi.org/10.1136/heartjnl-2012-301686.CrossRef

Kakihana Y, Ito T, Nakahara M, Yamaguchi K, Yasuda T. Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care. 2016;4:22. https://doi.org/10.1186/s40560-016-0148-1.CrossRefPubMedPubMedCentral

Van Tassell BW, Raleigh JMV, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep. 2015;12(1):33–41. https://doi.org/10.1007/s11897-014-0231-7.CrossRefPubMed

Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128(17):1910–23. https://doi.org/10.1161/CIRCULATIONAHA.113.003199.CrossRefPubMedPubMedCentral

10.

Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–147.PubMed

11.

Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu Rev Immunol. 2009;27:621–68. https://doi.org/10.1146/annurev.immunol.25.022106.141627.CrossRefPubMedPubMedCentral

12.

Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3(105):cm1. https://doi.org/10.1126/scisignal.3105cm1.PubMedCrossRef

13.

Cremer PC, Kumar A, Kontzias A, Tan CD, Rodriguez ER, Imazio M, Klein AL. Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment. J Am Coll Cardiol. 2016;68(21):2311–28. https://doi.org/10.1016/j.jacc.2016.07.785.CrossRefPubMed

14.

Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure–the whys and wherefores. Heart Fail Rev. 2006;11(1):83–92. https://doi.org/10.1007/s10741-006-9196-2.CrossRefPubMed

15.

Liu SJ, Zhou W, Kennedy RH. Suppression of beta-adrenergic responsiveness of L-type Ca²⁺ current by IL-1beta in rat ventricular myocytes. Am J Physiol. 1999;276(1 Pt 2):H141–8.PubMed

16.

Combes A, Frye CS, Lemster BH, Brooks SS, Watkins SC, Feldman AM, McTiernan CF. Chronic exposure to interleukin 1beta induces a delayed and reversible alteration in excitation-contraction coupling of cultured cardiomyocytes. Pflugers Arch. 2002;445(2):246–56. https://doi.org/10.1007/s00424-002-0921-y.CrossRefPubMed

17.

Tatsumi T, Matoba S, Kawahara A, Keira N, Shiraishi J, Akashi K, Kobara M, Tanaka T, Katamura M, Nakagawa C, Ohta B, Shirayama T, Takeda K, Asayama J, Fliss H, Nakagawa M. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol. 2000;35(5):1338–46.CrossRefPubMed

18.

Zell R, Geck P, Werdan K, Boekstegers P. Tnf-α and IL-1α inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: Evidence for primary impairment of mitochondrial function. Mol Cell Biochem. 1997;177(1):61–7. https://doi.org/10.1023/A:1006896832582.CrossRefPubMed

19.

Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684–91. https://doi.org/10.1161/CIRCHEARTFAILURE.109.873240.CrossRefPubMed

20.

Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail. 2014;7(3):418–26. https://doi.org/10.1161/CIRCHEARTFAILURE.113.001036.CrossRefPubMed

21.

Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Pina IL, Zannad F, Kraus WE, O’Connor CM. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013;6(6):1172–9. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000207.CrossRefPubMedPubMedCentral

22.

Daniels LB, Bayes-Genis A. Using ST2 in cardiovascular patients: a review. Future Cardiol. 2014;10(4):525–39. https://doi.org/10.2217/fca.14.36.CrossRefPubMed

23.

Van Tassell BW, Seropian IM, Toldo S, Mezzaroma E, Abbate A. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res Off J Eur Histamine Res Soc Al. 2013;62(7):637–40. https://doi.org/10.1007/s00011-013-0625-0.CrossRef

24.

Van Tassell BW, Arena RA, Toldo S, Mezzaroma E, Azam T, Seropian IM, Shah K, Canada J, Voelkel NF, Dinarello CA, Abbate A. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438. https://doi.org/10.1371/journal.pone.0033438.CrossRefPubMedPubMedCentral

25.

Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med. 1996;183(3):949–58.CrossRefPubMed

26.

Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M, Zhu S, Zhang R, Han W. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol. 2010;643(2–3):247–53. https://doi.org/10.1016/j.ejphar.2010.06.024.CrossRefPubMed

27.

Mezzaroma E, Mikkelsen RB, Toldo S, Mauro AG, Sharma K, Marchetti C, Alam A, Van Tassell BW, Gewirtz DA, Abbate A. Role of Interleukin-1 in Radiation-Induced Cardiomyopathy. Mol Med Camb Mass. 2015;21:210–8. https://doi.org/10.2119/molmed.2014.00243.PubMedPubMedCentralCrossRef

28.

Ikonomidis I, Lekakis JP, Nikolaou M, Paraskevaidis I, Andreadou I, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos PN, Kremastinos DT. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117(20):2662–9. https://doi.org/10.1161/CIRCULATIONAHA.107.731877.CrossRefPubMed

29.

Abbate A, Canada JM, Van Tassell BW, Wise CM, Dinarello CA. Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? Int J Cardiol. 2014;171(3):e125–6. https://doi.org/10.1016/j.ijcard.2013.12.078.CrossRefPubMed

30.

Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchior RD, Turlington JS, Thurber CJ, Christopher S, Dixon DL, Fronk DT, Thomas CS, Rose SW, Buckley LF, Dinarello CA, Biondi-Zoccai G, Abbate A. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, Placebo-Controlled Pilot Study. J Cardiovasc Pharmacol. 2016;67(6):544–51. https://doi.org/10.1097/FJC.0000000000000378.CrossRefPubMedPubMedCentral

31.

Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113(2):321–7. https://doi.org/10.1016/j.amjcard.2013.08.047.CrossRefPubMed

32.

Van Tassell BW, Buckley LF, Carbone S, Trankle CR, Canada JM, Dixon DL, Abouzaki N, Oddi-Erdle C, Biondi-Zoccai G, Arena R, Abbate A. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure anakinra response trial 2 (D-HART2). Clin Cardiol. 2017. https://doi.org/10.1002/clc.22719.PubMedCrossRefPubMedCentral

33.

Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res J Lab Clin Med. 2016;167(1):152–66. https://doi.org/10.1016/j.trsl.2015.07.002.CrossRef

34.

Lugrin J, Parapanov R, Rosenblatt-Velin N, Rignault-Clerc S, Feihl F, Waeber B, Muller O, Vergely C, Zeller M, Tardivel A, Schneider P, Pacher P, Liaudet L. Cutting edge: IL-1alpha is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol. 2015;194(2):499–503. https://doi.org/10.4049/jimmunol.1401948.CrossRefPubMed

35.

Dewald O, Ren G, Duerr GD, Zoerlein M, Klemm C, Gersch C, Tincey S, Michael LH, Entman ML, Frangogiannis NG. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol. 2004;164(2):665–77. https://doi.org/10.1016/S0002-9440(10)63154-9.CrossRefPubMedPubMedCentral

36.

Christia P, Bujak M, Gonzalez-Quesada C, Chen W, Dobaczewski M, Reddy A, Frangogiannis NG. Systematic characterization of myocardial inflammation, repair, and remodeling in a mouse model of reperfused myocardial infarction. J Histochem Cytochem Off J Histochem Soc. 2013;61(8):555–70. https://doi.org/10.1369/0022155413493912.CrossRef

37.

Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81(2):487–98. https://doi.org/10.1172/JCI113346.CrossRefPubMedPubMedCentral

38.

Offner FA, Feichtinger H, Stadlmann S, Obrist P, Marth C, Klingler P, Grage B, Schmahl M, Knabbe C. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol. 1996;148(5):1679–88.PubMedPubMedCentral

39.

Cozzolino F, Torcia M, Aldinucci D, Ziche M, Almerigogna F, Bani D, Stern DM. Interleukin 1 is an autocrine regulator of human endothelial cell growth. Proc Natl Acad Sci USA. 1990;87(17):6487–91.CrossRefPubMedPubMedCentral

40.

Bochner BS, Luscinskas FW, Gimbrone MAJ, Newman W, Sterbinsky SA, Derse-Anthony CP, Klunk D, Schleimer RP. Adhesion of human basophils, eosinophils, and neutrophils to interleukin. J Exp Med. 1991;173(6):1553–7.CrossRefPubMed

41.

Grames M, Breviario F, Pintucci G, Millet I, Dejana E, van Damme J, Donati MB, Mussoni L. Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. Biochem Biophys Res Commun. 1986;139(2):720–7.CrossRefPubMed

42.

Alfaidi M, Wilson H, Daigneault M, Burnett A, Ridger V, Chamberlain J, Francis S. Neutrophil elastase promotes interleukin-1beta secretion from human coronary endothelium. J Biol Chem. 2015;290(40):24067–78. https://doi.org/10.1074/jbc.M115.659029.CrossRefPubMedPubMedCentral

43.

Chai M, Zhang H-T, Zhou Y-J, Ji Q-W, Yang Q, Liu Y-Y, Zhao Y-X, Shi D-M, Liu W, Yang L-X, Zhang L-L, Liang J. Elevated IL-37 levels in the plasma of patients with severe coronary artery calcification. J Geriatr Cardiol JGC. 2017;14(5):285–91. https://doi.org/10.11909/j.issn.1671-5411.2017.05.013.PubMedCrossRef

44.

Liu Z, Zhang M, Wu J, Zhou P, Liu Y, Wu Y, Yang Y, Lu X. Serum CD121a (Interleukin 1 Receptor, Type I): a potential novel inflammatory marker for coronary heart disease. PLoS One. 2015;10(6):e0131086. https://doi.org/10.1371/journal.pone.0131086.CrossRefPubMedPubMedCentral

45.

Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, Frangogiannis NG. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol. 2008;173(1):57–67. https://doi.org/10.2353/ajpath.2008.070974.CrossRefPubMedPubMedCentral

46.

Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, Biondi-Zoccai GGL, Houser J-E, Qureshi IZ, Ownby ED, Gustini E, Biasucci LM, Severino A, Capogrossi MC, Vetrovec GW, Crea F, Baldi A, Kukreja RC, Dobrina A. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117(20):2670–83. https://doi.org/10.1161/CIRCULATIONAHA.107.740233.CrossRefPubMed

47.

Toldo S, Mezzaroma E, Van Tassell BW, Farkas D, Marchetti C, Voelkel NF, Abbate A. Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013;98(3):734–45. https://doi.org/10.1113/expphysiol.2012.069831.CrossRefPubMed

48.

Ikonomidis I, Tzortzis S, Andreadou I, Paraskevaidis I, Katseli C, Katsimbri P, Pavlidis G, Parissis J, Kremastinos D, Anastasiou-Nana M, Lekakis J. Increased benefit of interleukin-1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. Circ Cardiovasc Imaging. 2014;7(4):619–28. https://doi.org/10.1161/CIRCIMAGING.113.001193.CrossRefPubMed

49.

Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GGL, Van Tassell BW, Robati R, Roach LM, Arena RA, Roberts CS, Varma A, Gelwix CC, Salloum FN, Hastillo A, Dinarello CA, Vetrovec GW. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105(10):1371–7. https://doi.org/10.1016/j.amjcard.2009.12.059.CrossRefPubMed

50.

Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–400. https://doi.org/10.1016/j.amjcard.2013.01.287.CrossRefPubMedPubMedCentral

51.

Abbate A, Kontos MC, Abouzaki NA, Melchior RD, Thomas C, Van Tassell BW, Oddi C, Carbone S, Trankle CR, Roberts CS, Mueller GH, Gambill ML, Christopher S, Markley R, Vetrovec GW, Dinarello CA, Biondi-Zoccai G. Comparative safety of interleukin-1 blockade with anakinra in patients with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol. 2015;115(3):288–92. https://doi.org/10.1016/j.amjcard.2014.11.003.CrossRefPubMed

52.

Morton AC, Rothman AMK, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–84. https://doi.org/10.1093/eurheartj/ehu272.CrossRefPubMed

53.

Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

54.

Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2017;390(10105):1833–42. https://doi.org/10.1016/S0140-6736(17)32247-X.CrossRef

55.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet Lond Engl. 2017. https://doi.org/10.1016/S0140-6736(17)32814-3.CrossRef

56.

Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605–13.CrossRefPubMed

57.

Li YH, Rozanski GJ. Effects of human recombinant interleukin-1 on electrical properties of guinea pig ventricular cells. Cardiovasc Res. 1993;27(3):525–30.CrossRefPubMed

58.

Mitrokhin VM, Mladenov MI, Kamkin AG. IL-1 provokes electrical abnormalities in rat atrial myocardium. Int Immunopharmacol. 2015;28(1):780–4. https://doi.org/10.1016/j.intimp.2015.08.006.CrossRefPubMed

59.

Monnerat G, Alarcon ML, Vasconcellos LR, Hochman-Mendez C, Brasil G, Bassani RA, Casis O, Malan D, Travassos LH, Sepulveda M, Burgos JI, Vila-Petroff M, Dutra FF, Bozza MT, Paiva CN, Carvalho AB, Bonomo A, Fleischmann BK, de Carvalho ACC, Medei E. Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat Commun. 2016;7:13344. https://doi.org/10.1038/ncomms13344.CrossRefPubMedPubMedCentral

60.

El Khoury N, Mathieu S, Fiset C. Interleukin-1beta reduces L-type Ca²⁺ current through protein kinase C activation in mouse heart. J Biol Chem. 2014;289(32):21896–908. https://doi.org/10.1074/jbc.M114.549642.CrossRefPubMedPubMedCentral

61.

Duncan DJ, Yang Z, Hopkins PM, Steele DS, Harrison SM. TNF-alpha and IL-1beta increase Ca²⁺ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium. 2010;47(4):378–86. https://doi.org/10.1016/j.ceca.2010.02.002.CrossRefPubMedPubMedCentral

62.

Patten M, Hartogensis WE, Long CS. Interleukin-1beta is a negative transcriptional regulator of alpha1-adrenergic induced gene expression in cultured cardiac myocytes. J Biol Chem. 1996;271(35):21134–41.CrossRefPubMed

63.

McTiernan CF, Lemster BH, Frye C, Brooks S, Combes A, Feldman AM. Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res. 1997;81(4):493–503.CrossRefPubMed

64.

Baum JR, Long B, Cabo C, Duffy HS. Myofibroblasts cause heterogeneous Cx43 reduction and are unlikely to be coupled to myocytes in the healing canine infarct. Am J Physiol Heart Circ Physiol. 2012;302(3):H790–800. https://doi.org/10.1152/ajpheart.00498.2011.CrossRefPubMed

65.

De Jesus NM, Wang L, Herren AW, Wang J, Shenasa F, Bers DM, Lindsey ML, Ripplinger CM. Atherosclerosis exacerbates arrhythmia following myocardial infarction: role of myocardial inflammation. Heart Rhythm. 2015;12(1):169–78. https://doi.org/10.1016/j.hrthm.2014.10.007.CrossRefPubMed

66.

Adlan AM, Panoulas VF, Smith JP, Fisher JP, Kitas GD. Association between corrected QT interval and inflammatory cytokines in rheumatoid arthritis. J Rheumatol. 2015;42(3):421–8. https://doi.org/10.3899/jrheum.140861.CrossRefPubMed

67.

Pisoni CN, Reina S, Arakaki D, Eimon A, Carrizo C, Borda E. Elevated IL-1beta levels in anti-Ro/SSA connective tissue diseases patients with prolonged corrected QTc interval. Clin Exp Rheumatol. 2015;33(5):715–20.PubMed

68.

Sordillo PP, Sordillo DC, Helson L. Review: the prolonged QT interval: role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways. Vivo Athens Greece. 2015;29(6):619–36.

69.

Cheng T, Wang X-F, Hou Y-T, Zhang L. Correlation between atrial fibrillation, serum amyloid protein A and other inflammatory cytokines. Mol Med Rep. 2012;6(3):581–4. https://doi.org/10.3892/mmr.2012.934.CrossRefPubMed

70.

Gungor B, Ekmekci A, Arman A, Ozcan KS, Ucer E, Alper AT, Calik N, Yilmaz H, Tezel T, Coker A, Bolca O. Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation. Pacing Clin Electrophysiol PACE. 2013;36(10):1220–7. https://doi.org/10.1111/pace.12182.PubMedCrossRef

71.

Xu B, Harb SC, Cremer PC. New insights into pericarditis: mechanisms of injury and therapeutic targets. Curr Cardiol Rep. 2017;19(7):60. https://doi.org/10.1007/s11886-017-0866-6.CrossRefPubMed

72.

Imazio M. Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options. Expert Rev Clin Immunol. 2014;10(11):1487–92. https://doi.org/10.1586/1744666X.2014.965150.CrossRefPubMed

73.

Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–11. https://doi.org/10.1007/s12016-011-8294-7.CrossRefPubMedPubMedCentral

74.

Jain S, Thongprayoon C, Espinosa RE, Hayes SN, Klarich KW, Cooper LT, Moder KG, Anavekar NS, Oh JK, Matteson EL. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116(8):1277–9. https://doi.org/10.1016/j.amjcard.2015.07.047.CrossRefPubMed

75.

Lazaros G, Vasileiou P, Koutsianas C, Antonatou K, Stefanadis C, Pectasides D, Vassilopoulos D. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73(12):2215–7. https://doi.org/10.1136/annrheumdis-2014-205990.CrossRefPubMed

76.

Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, Marcolongo R, Lorini M, Rimini A, Valenti A, Erre GL, Sormani MP, Belli R, Gaita F, Martini A. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906–12. https://doi.org/10.1001/jama.2016.15826.CrossRefPubMed

77.

Kim B, Lee Y, Kim E, Kwak A, Ryoo S, Bae SH, Azam T, Kim S, Dinarello CA. The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol. 2013;4:391. https://doi.org/10.3389/fimmu.2013.00391.PubMedPubMedCentralCrossRef

78.

Toldo S, Kannan H, Bussani R, Anzini M, Sonnino C, Sinagra G, Merlo M, Mezzaroma E, De-Giorgio F, Silvestri F, Van Tassell BW, Baldi A, Abbate A. Formation of the inflammasome in acute myocarditis. Int J Cardiol. 2014;171(3):e119–21. https://doi.org/10.1016/j.ijcard.2013.12.137.CrossRefPubMed

79.

Satoh M, Nakamura M, Akatsu T, Iwasaka J, Shimoda Y, Segawa I, Hiramori K. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci Lond Engl. 2003;104(6):577–84. https://doi.org/10.1042/cs20020263.CrossRef

80.

Blyszczuk P, Kania G, Dieterle T, Marty RR, Valaperti A, Berthonneche C, Pedrazzini T, Berger CT, Dirnhofer S, Matter CM, Penninger JM, Luscher TF, Eriksson U. Myeloid differentiation factor-88/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res. 2009;105(9):912–20. https://doi.org/10.1161/CIRCRESAHA.109.199802.CrossRefPubMed

81.

Gupta S, Markham DW, Drazner MH, Mammen PP. Fulminant myocarditis. Nat Clin Pract Cardiovasc Med. 2008;5(11):693–706. https://doi.org/10.1038/ncpcardio1331.CrossRefPubMed

82.

Parisi F, Paglionico A, Varriano V, Ferraccioli G, Gremese E. Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis: a case report treated with high doses (8 mg/kg/d) of anakinra. Medicine (Baltimore). 2017;96(24):e6656. https://doi.org/10.1097/MD.0000000000006656.CrossRef

83.

Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:131. https://doi.org/10.3389/fimmu.2017.00131.CrossRefPubMedPubMedCentral

84.

Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. J Intensive Care. 2015;3:48. https://doi.org/10.1186/s40560-015-0112-5.CrossRefPubMedPubMedCentral

85.

Papaioannou VE (2015) Frontiers in myocardia: septic cardiomyopathy from bench-to-bedside. Bentham Science Publishers. https://books.google.co.il/books?id=yfn8DQAAQBAJ

86.

Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation. 1986;73(4):637–44.CrossRefPubMed

87.

88.

Kumar A, Brar R, Wang P, Dee L, Skorupa G, Khadour F, Schulz R, Parrillo JE. Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol. 1999;276(1 Pt 2):R265–76.PubMed

Title: A Review of Interleukin-1 in Heart Disease: Where Do We Stand Today?
Authors: Yishay Szekely
Yaron Arbel
Publication date: 01-06-2018
Publisher: Springer Healthcare
Published in: Cardiology and Therapy / Issue 1/2018
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-018-0104-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2018

Cardiovascular Complications of Marijuana and Related Substances: A Review

Pulmonary Embolism Following Incomplete Surgical Resection of a Right Ventricular Myxoma: A Case Report and Review of the Literature

Correction to: Exosomes in Cardiovascular Medicine

Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris

The Effect of Spironolactone on the Incidence of Contrast-Induced Nephropathy in Patients Undergoing Cardiac Catheterization: Study Design and Rationale

Impact of Antithrombotic Regimen on Mortality, Ischemic, and Bleeding Outcomes after Transcatheter Aortic Valve Replacement

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage